A Study for Observing Severe Asthma in Patients Treated With Tezepelumab

Korábbi kezelés

• Participants on concurrent biologics for asthma at the time of receiving the first dose of Tezepelumab will be excluded except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment)

Egyéb

• Any contraindication to Tezepelumab
• Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months
• Pregnancy or lactation period.

• Male or female participants aged 12 years or older
• Provision of signed and dated written informed consent, including assent for minors
• Prescribed treatment with Tezepelumab
• Diagnosis of asthma for at least 52 weeks prior to enrolment date and symptoms confirmed by the Investigator not to be due to alternative diagnoses
• Received at least one prescription of medium-dose to high-dose inhaled corticosteroids (ICS) during the 52 weeks prior to enrolment date
• Use of additional asthma maintenance controller medication(s) for at least 52 weeks prior to enrolment date
• Documented history of at least 1 asthma exacerbations during the 52 weeks prior to enrolment date
• Individuals with ACQ-6 score ≥ 1.5 (indicating inadequate asthma symptom control) at enrolment or up to 12 weeks before enrolment
• Participants currently receiving care from pulmonologists and/or allergists
• Participants who are able to understand and complete the ePROs
• Availability of participants medical records for asthma exacerbation and Healthcare Resource Utilization (HCRU) for the 52 weeks prior to Tezepelumab initiation